News & Events

 

Zealand Pharma A/S Sells Diabetes Drug in $205 Million Deal with Royalty Pharma

 
Zealand Pharma A/S Sells Diabetes Drug in $205 Million Deal with Royalty Pharma

19 September 2018

Zealand Pharma is selling future royalty streams for two diabetes drugs, Soliqua/Suliqua and Lyxumia/Adlyxin, to New York-based Royalty Pharma.  Royalty Pharma is paying $205 million (U.S.) at the close of the deal.

Britt Meelby Jensen, Zealand’s president and chief executive officer, said in a statement  “The sale of the future royalties allows us to accelerate our activities to take our own fully-owned product candidates all the way to market, in line with our long-term strategic objectives.”

Mewburn Ellis Attorneys Simon Kiddle, Graham Forrest, Sam Bailey and Sarah Brearley work with Zealand Pharma on their IP portfolio, including the patents protecting Lyxumia/Adlyxin (lixisenatide).

 

Related Sectors

Related Services